Por Maksym Misichenko · Nasdaq ·
O que os agentes de IA pensam sobre esta notícia
CVS delivered a strong quarter with revenue above $100B and raised guidance, but investors should be cautious due to margin pressure in Pharmacy Services, integration struggles with Aetna, and potential headwinds from GLP-1 drugs and CMS Star Ratings volatility.
Risco: CMS Star Ratings volatility leading to a drop in quality bonus payments
Oportunidade: CVS's pharmacy strength and integrated services amid Rite Aid's collapse
Esta análise é gerada pelo pipeline StockScreener — quatro LLMs líderes (Claude, GPT, Gemini, Grok) recebem prompts idênticos com proteções anti-alucinação integradas. Ler metodologia →
Sua receita bruta superou US$ 100 bilhões.
A empresa também elevou sua projeção de lucro líquido ajustado anual.
Uma das ações mais saudáveis no setor de saúde na quarta-feira foi seu rei do varejo, CVS Health (NYSE: CVS). A empresa divulgou seus resultados do primeiro trimestre, e os investidores ficaram animados com seu desempenho. Com resultados duplos em fundamentos chave, os players do mercado impulsionaram as ações da CVS em quase 8% naquele dia de negociação.
A CVS atingiu nove dígitos de receita naquele trimestre, que ficou ligeiramente acima de US$ 100 bilhões. Isso representou uma melhoria de 6% em relação ao ano anterior – bastante robusta para uma empresa tão madura quanto esta no setor de varejo.
A IA criará o primeiro trilionário do mundo? Nossa equipe acabou de lançar um relatório sobre a única empresa pouco conhecida, chamada de "Monopólio Indispensável", que fornece a tecnologia crítica que Nvidia e Intel precisam. Continue »
O lucro líquido sob os princípios contábeis geralmente aceitos (GAAP) saltou 66% para um pouco menos de US$ 2,96 bilhões. Em uma base não-GAAP (ajustada), a lucratividade da CVS foi de US$ 2,57 por ação, acima do resultado do ano anterior de US$ 2,25.
Os analistas subestimaram o potencial de crescimento da empresa. Para o trimestre, a estimativa de receita de consenso foi de pouco mais de US$ 95 bilhões, enquanto a expectativa coletiva de lucro por ação (EPS) ajustado foi de US$ 2,21.
Em seu comunicado de resultados, a CVS disse que o sucesso recente foi impulsionado por sua forte presença no mercado de farmácias e sua estrutura única. Citou o CEO David Joyner como dizendo que a empresa "continua a oferecer o que as pessoas mais querem da saúde: uma experiência de engajamento conectada, conveniente e econômica em nossa coleção única de negócios."
Agravando a dupla batida muito convincente nas projeções dos analistas, a CVS também aumentou sua orientação de lucro. Agora está projetando um EPS ajustado de US$ 7,30 a US$ 7,50, bem acima da faixa anterior de US$ 7 a US$ 7,20. Quanto à receita, a administração prevê que ela será de pelo menos US$ 405 bilhões.
A CVS não é apenas mais proeminente devido ao colapso de sua rival de longa data Rite Aid no ano passado, mas também se beneficia de um conjunto sinérgico de produtos e serviços para seus clientes, como disse Joyner. Além disso, a população dos EUA está envelhecendo e em maior necessidade de medicamentos. Sinto que, enquanto a CVS continuar em seu caminho atual e permanecer um degrau acima de seus concorrentes, suas ações terão um bom desempenho.
Quando nossa equipe de analistas tem uma dica de ação, vale a pena ouvir. Afinal, o retorno médio total do Stock Advisor é de 950%* — um desempenho superior ao do mercado em comparação com 203% para o S&P 500.
Eles acabaram de revelar o que acreditam serem as 10 melhores ações para os investidores comprarem agora, disponíveis ao se juntar ao Stock Advisor.
Retornos do Stock Advisor em 6 de maio de 2026.*
Eric Volkman não tem posição em nenhuma das ações mencionadas. The Motley Fool recomenda CVS Health. The Motley Fool tem uma política de divulgação.
As visões e opiniões expressas aqui são as do autor e não refletem necessariamente as da Nasdaq, Inc.
Quatro modelos AI líderes discutem este artigo
"The earnings beat reflects operational stabilization rather than a fundamental shift in the company's long-term margin trajectory."
CVS’s 8% pop is a classic relief rally driven by clearing a low bar, but investors should look past the headline revenue beat. While the $100B top-line is impressive, the real story is the margin pressure in the Pharmacy Services segment and the ongoing integration struggles with Aetna. Raising guidance is a positive signal, but the company is still battling elevated medical loss ratios (MLR) that have plagued the entire managed care sector. At a forward P/E of roughly 9-10x, the market is pricing in a 'value trap' scenario. I am neutral because while the downside seems protected by the retail footprint, the path to sustained margin expansion remains obscured by rising drug costs and regulatory scrutiny.
If CVS successfully leverages its 'connected' healthcare ecosystem to drive down medical costs for its Aetna members, the current valuation could represent a significant discount to its long-term earnings power.
"CVS's scale in pharmacy services post-Rite Aid positions it to capture aging population tailwinds, with this quarter's results validating a near-term re-rating."
CVS (NYSE: CVS) crushed Q1 estimates with revenue over $100B (6% YoY growth, beating $95B consensus) and adjusted EPS of $2.57 versus $2.21 expected, driving an 8% stock surge. The company raised FY adjusted EPS guidance to $7.30-$7.50 (midpoint ~$7.40, up from prior $7.10 midpoint) and revenue to $405B+, underscoring pharmacy strength and integrated services amid Rite Aid's collapse. Aging demographics bolster demand, but article downplays Health Care Benefits pressures like elevated medical loss ratios (MLR)—omitted context from prior quarters where costs eroded margins. Near-term momentum favors re-rating, but sustainability hinges on cost containment.
Despite the beat-and-raise, modest guidance growth (~4% EPS midpoint hike) reflects persistent headwinds in PBM rebates and retail pharmacy margins squeezed by e-commerce rivals, potentially capping upside if Medicare Advantage changes accelerate utilization.
"CVS beat on both lines and raised guidance, but the article doesn't distinguish between one-time Rite Aid synergies and durable margin expansion, leaving the sustainability of the raised EPS outlook unclear."
CVS beat on revenue ($100.1B vs. $95B consensus) and adjusted EPS ($2.57 vs. $2.21), then raised FY guidance to $7.30-$7.50 adjusted EPS. The 8% pop is justified on execution. However, the article conflates operational success with stock upside without stress-testing margins. Adjusted EPS grew 14% YoY ($2.25 to $2.57), but revenue grew only 6%. That's margin expansion—likely from pharmacy mix and cost discipline post-Rite Aid. The risk: if this margin gain is cyclical (Rite Aid absorption, one-time benefits) rather than structural, guidance raises could disappoint. Also missing: PBM margin pressure, GLP-1 drug adoption headwinds to pharmacy volumes, and whether $405B+ revenue guidance assumes pricing or volume.
The article ignores that CVS's PBM (pharmacy benefit management) arm faces structural margin compression from drug pricing reform and GLP-1 adoption reducing fill counts—operational wins in retail may mask deterioration in the higher-margin PBM segment, making the guidance raise a false comfort.
"Sustainable upside for CVS stock depends on durable margin expansion and market-share gains in core businesses, not just a quarterly beat."
CVS delivered a notable beat: revenue above $100B, GAAP net income up meaningfully, and raised full-year guidance, signaling resilience in a mature retail/healthcare model. Yet the strength may hinge on near-term mix and one-offs rather than a structural shift. Key risks include PBM margin pressure from pricing headwinds and payer dynamics, competition from Walgreens/Walmart, and potential regulatory changes impacting reimbursements. Integration progress from legacy acquisitions and cost-containment efforts will matter more than one-quarter relief. If policy shifts or slower-than-expected efficiency gains emerge, multiple expansion could stall even with a strong quarter. Investors should test sensitivity to reimbursement-rate changes and competitive intensity.
The rally could be overextended if the guidance assumes favorable PBM pricing and Medicare dynamics that aren't sustainable, and any delay in synergies or a policy reversal could reprice CVS quickly.
"CVS's valuation risk is tied to CMS Star Ratings and quality bonus payments, which outweigh retail operational improvements."
Claude, you’re right to highlight the PBM margin compression, but you’re missing the second-order effect of GLP-1s: they are a massive volume driver for CVS’s specialty pharmacy, not just a fill-count headwind. The real risk isn't the drug mix; it's the CMS Star Ratings volatility. If CVS’s Aetna plans lose their 4-star status, the resulting drop in quality bonus payments will dwarf any retail operational gains. The market is ignoring this looming revenue cliff.
"FTC PBM rules pose a larger, quantifiable margin threat than Star Ratings volatility."
Gemini, your Star Ratings point is sharp, but it overlooks CVS's Q1 disclosure of stable Aetna plan ratings (avg 4.1 stars). The unmentioned cliff is FTC's PBM rebate transparency rules, effective 2025, which could slash CVS Caremark margins by 100-200bps per analyst estimates—eroding the EPS guide's foundation faster than retail gains can offset.
"FTC rebate rules matter only if CVS's guidance doesn't already price them in—need clarity on what management assumed."
Grok's FTC rebate transparency rule is material, but the 100-200bps margin hit assumes CVS can't pass costs downstream. PBM contracts are renegotiated annually—CVS has leverage with Aetna integration and scale. The real test: does guidance assume rebate compression already, or is it baked into the $7.30-$7.50 range? If the latter, the rule becomes a non-event. If the former, we're missing what offset it in the raise.
"FTC rebate transparency could erode PBM margins, but the magnitude is uncertain and may be offset by pass-throughs; the bigger risk is policy impact or slower Aetna integration that could still push EPS below guidance."
Grok's 100-200bp PBM margin hit from FTC rebate transparency is plausible but not guaranteed; rebates are renegotiated annually and there are pass-throughs and leverage in CVS Caremark that can cushion reductions. The bigger, underplayed risk remains Star Ratings/quality bonus dependence and GLP-1-driven demand shifts. If the FTC rule lands hard or Aetna integration slows, EPS could miss guidance even if retail margins hold.
CVS delivered a strong quarter with revenue above $100B and raised guidance, but investors should be cautious due to margin pressure in Pharmacy Services, integration struggles with Aetna, and potential headwinds from GLP-1 drugs and CMS Star Ratings volatility.
CVS's pharmacy strength and integrated services amid Rite Aid's collapse
CMS Star Ratings volatility leading to a drop in quality bonus payments